These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33248510)

  • 61. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda.
    Zakiyah N; van Asselt ADI; Setiawan D; Cao Q; Roijmans F; Postma MJ
    Appl Health Econ Health Policy; 2019 Feb; 17(1):65-76. PubMed ID: 30178267
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
    Kondili LA; Gamkrelidze I; Blach S; Marcellusi A; Galli M; Petta S; Puoti M; Vella S; Razavi H; Craxi A; Mennini FS;
    Liver Int; 2020 Jul; 40(7):1545-1555. PubMed ID: 32078234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan.
    Zhuo Y; Hayashi T; Chen Q; Aggarwal R; Hutin Y; Chhatwal J
    Sci Rep; 2020 Mar; 10(1):4089. PubMed ID: 32139872
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
    Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
    Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
    Basu S; Bendavid E; Sood N
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
    Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
    Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.
    Mafirakureva N; Mapako T; Khoza S; Emmanuel JC; Marowa L; Mvere D; Postma MJ; van Hulst M
    Transfusion; 2016 Dec; 56(12):3101-3111. PubMed ID: 27696441
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation.
    Zhang L; Tao Y; Woodring J; Rattana K; Sovannarith S; Rathavy T; Cheang K; Hossain S; Ferradini L; Deng S; Sokun C; Samnang C; Nagai M; Lo YR; Ishikawa N
    Int J Epidemiol; 2019 Aug; 48(4):1327-1339. PubMed ID: 30879066
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
    Chhatwal J; Kanwal F; Roberts MS; Dunn MA
    Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.
    Tskhomelidze I; Shadaker S; Kuchuloria T; Gvinjilia L; Butsashvili M; Nasrullah M; Gabunia T; Gamkrelidze A; Getia V; Sharvadze L; Tsertsvadze T; Zarqua J; Tsanava S; Handanagic S; Armstrong PA; Averhoff F; Vickerman P; Walker JG
    Liver Int; 2023 Mar; 43(3):558-568. PubMed ID: 36129625
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.
    Ishizaki A; Bouscaillou J; Luhmann N; Liu S; Chua R; Walsh N; Hess S; Ivanova E; Roberts T; Easterbrook P
    BMC Infect Dis; 2017 Nov; 17(Suppl 1):696. PubMed ID: 29143609
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness analysis of an additional birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique.
    Klingler C; Thoumi AI; Mrithinjayam VS
    Vaccine; 2012 Dec; 31(1):252-9. PubMed ID: 22902676
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Universal testing for hepatitis B and hepatitis C in the emergency department: a cost-effectiveness and budget impact analysis of two urban hospitals in the United Kingdom.
    Williams J; Vickerman P; Smout E; Page EE; Phyu K; Aldersley M; Nebbia G; Douthwaite S; Hunter L; Ruf M; Miners A
    Cost Eff Resour Alloc; 2022 Nov; 20(1):60. PubMed ID: 36376920
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost effectiveness of a government supported policy strategy to decrease sodium intake: global analysis across 183 nations.
    Webb M; Fahimi S; Singh GM; Khatibzadeh S; Micha R; Powles J; Mozaffarian D
    BMJ; 2017 Jan; 356():i6699. PubMed ID: 28073749
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
    Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
    Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
    Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
    Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.